Evaluation of recent evidence on the solubility of beryllium compounds and cancer risk.

aTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York bExponent Inc., Menlo Park, California cExponent Inc., Bellevue, Washington, USA Received 12 December 2018 Accepted 7 May 2019 Correspondence to Paolo Boffetta, MD, MPH, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1130, New York, NY 10029, USA, Tel: +1 212 824 7378; fax +1 212 849 2566; e-mail: [email protected]